{
  "id": "58a326da60087bc10a00000e",
  "type": "list",
  "question": "List drugs withdrawn from the market for cardiovascular adverse events.",
  "ideal_answer": "Over the years, a number of different drugs have been withdrawn for Cardiotoxicity. Drugs like Clobutinol, that  induce cardiac arrhythmias by a blockade of the potassium channel coded by the hERG channel, sibutramine for weight loss and Cox2 inhibitors, Rofecoxib and Valdecoxib have been withdrawn from the market.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/21265828",
    "http://www.ncbi.nlm.nih.gov/pubmed/21412876",
    "http://www.ncbi.nlm.nih.gov/pubmed/26934640",
    "http://www.ncbi.nlm.nih.gov/pubmed/25084209",
    "http://www.ncbi.nlm.nih.gov/pubmed/21249650",
    "http://www.ncbi.nlm.nih.gov/pubmed/19034038",
    "http://www.ncbi.nlm.nih.gov/pubmed/16255660",
    "http://www.ncbi.nlm.nih.gov/pubmed/19933959",
    "http://www.ncbi.nlm.nih.gov/pubmed/25114779",
    "http://www.ncbi.nlm.nih.gov/pubmed/23424288",
    "http://www.ncbi.nlm.nih.gov/pubmed/16119973",
    "http://www.ncbi.nlm.nih.gov/pubmed/25806762",
    "http://www.ncbi.nlm.nih.gov/pubmed/25340915",
    "http://www.ncbi.nlm.nih.gov/pubmed/21751825",
    "http://www.ncbi.nlm.nih.gov/pubmed/18782007"
  ],
  "snippets": [
    {
      "text": " rofecoxib was voluntarily removed from the market for increased cardiovascular risk and in April 2005, valdecoxib was also withdrawn, at least in part, due to excess cardiovascular risk.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16255660",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A common over-the-counter (OTC) non-opioid antitussive drug, clobutinol, was recently withdrawn from the market due to its potential to induce cardiac arrhythmias by a blockade of the potassium channel coded by the human ether-\u00e0-go-go-related gene (hERG).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19034038",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "n. However, despite this, at the time of writing orlistat (Europe; USA) remains the only drug currently marketed for the treatment of obesity, with sibutramine having recently been withdrawn from sale globally due to the increased incidence of serious, non-fatal cardiovascular events",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21265828",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Diclofenac has a risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424288",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sibutramine was associated with an increase in major adverse cardiovascular events in the Sibutramine Cardiovascular Outcomes (SCOUT) trial and it was withdrawn from the market in 2010",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25114779",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The safety of the most popular agent, aprotinin, has been challenged, and it was withdrawn from world markets in May 2008 because of concerns that it increased the risk of cardiovascular complications and death.To assess the comparative effects of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon aminocaproic acid (EACA) on blood loss during surgery, the need for red blood cell (RBC) transfusion, and adverse events, particularly vascular occlusion, renal dysfunction, and death.We searched: the Cochrane Injuries Groups Specialised Register (July 2010), Cochrane Central Register of Controlled Trials (The Cochrane Library 2010, Issue 3), MEDLINE (Ovid SP) 1950 to July 2010, EMBASE (Ovid SP) 1980 to July 2010.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21412876",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The safety of the most popular agent, aprotinin, has been challenged, and it was withdrawn from world markets in May 2008 because of concerns that it increased the risk of cardiovascular complications and death.To assess the comparative effects of the anti-fibrinolytic drugs aprotinin, tranexamic acid (TXA), and epsilon aminocaproic acid (EACA) on blood loss during surgery, the need for red blood cell (RBC) transfusion, and adverse events, particularly vascular occlusion, renal dysfunction, and death.We searched: the Cochrane Injuries Groups Specialised Register (July 2010), Cochrane Central Register of Controlled Trials (The Cochrane Library 2010, Issue 3), MEDLINE (Ovid SP) 1950 to July 2010, EMBASE (Ovid SP) 1980 to July 2010.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249650",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rofecoxib and valdecoxib have been withdrawn from the market worldwide due to safety concerns (most importantly for cardiovascular adverse events) and lumiracoxib has been withdrawn in many countries due to liver toxicity",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340915",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the SCOUT (Sibutramine Cardiovascular OUTcomes) study, sibutramine increased serious cardiovascular events, such as stroke or myocardial infarction, compared with placebo, and was consequently withdrawn from the market",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21751825",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Diclofenac has a risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular toxicity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424288",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Rofecoxib and valdecoxib have been withdrawn from the market worldwide due to safety concerns (most importantly for cardiovascular adverse events) and lumiracoxib has been withdrawn in many countries due to liver toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25340915",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sertindole , first withdrawn from the market for cardiovascular safety concerns, is currently available in many countries.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25084209",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the SCOUT (Sibutramine Cardiovascular OUTcomes) study, sibutramine increased serious cardiovascular events, such as stroke or myocardial infarction, compared with placebo, and was consequently withdrawn from the market. The lesson learnt from this is the importance of patient selection, limiting the duration of treatment and stopping treatment in non-responders. Currently, phentermine and amfepramone (diethylpropion) are approved for short-term treatment of obesity (up to 3 months) and orlistat is approved for longer-term treatment; however, the gastrointestinal adverse effects of orlistat may be intolerable for some patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21751825",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Certain non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., rofecoxib [Vioxx]) increase the risk of heart attack and stroke and should be avoided in patients at high risk of cardiovascular events.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424288",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the SCOUT (Sibutramine Cardiovascular OUTcomes) study, sibutramine increased serious cardiovascular events, such as stroke or myocardial infarction, compared with placebo, and was consequently withdrawn from the market.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21751825",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Diclofenac has a risk very similar to rofecoxib, which was withdrawn from worldwide markets owing to cardiovascular toxicity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23424288",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Rofecoxib, a selective cyclo-oxygenase (COX)-2 inhibitor, was a widely marketed drug that was used for relief of pain and inflammation in arthritic conditions. It was withdrawn from the market worldwide in September 2004 because of an increased risk of cardiovascular events. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16119973",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064420",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000069451"
  ],
  "exact_answer": "Rofecoxib, Valdecoxib, Sibutramine, Clobutinol, Sertindole, aprotinin"
}